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Despite the high specificity of endomyocardial biopsy for 
detecting CS, the sensitivity is relatively low, ranging from 
20% to 63%, because of the non-uniformity of granulomas in 
cardiac tissue.8,9
Emerging imaging modalities, particularly myocardial thal-
lium-201 scintigraphy, 18-fluoro-deoxyglucose positron emis-
sion tomography (FDG-PET) and cardiac magnetic resonance 
(CMR) combined with late gadolinium enhanced (LGE) imag-
ing (LGE-CMR) and gallium-67 (Ga) uptake, have markedly 
improved the sensitivity and specificity of CS diagnosis10–14 
and been shown to have prognostic value for predicting clini-
cal outcomes in CS patients.15–21 Nevertheless, echocardiogra-
phy is less expensive and more practically useful for the initial 
diagnostic screening of CS patients.22,23 It would be useful 
to identify a reliable echocardiographic indicator for the 
ardiac sarcoidosis (CS) is characterized by the forma-
tion of non-caseating granulomas, most commonly in 
the myocardium and conduction system, particularly 
the interventricular septum (IVS) and free wall of the left 
ventricle (LV).1–5 Although common clinical manifestations 
of CS are impaired systolic LV function, atrioventricular block 
(AVB), ventricular arrhythmias, and sudden cardiac death,6 
predictors of these adverse events at the time of diagnosis 
have not been well determined.
The gold standard for the diagnosis of CS is pathological 
evidence obtained by endomyocardial biopsy. In 1993, the 
Japanese Ministry of Health and Welfare published a set of 
diagnostic criteria for CS that require direct evidence of sar-
coid granulomas from endomyocardial biopsy or indirect evi-
dence of inflammatory myocardial lesions in extra-CS patients.7 
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Background: Basal thinning of the interventricular septum (IVS) is an important diagnostic feature of cardiac sar-
coidosis (CS), but its long-term prognostic significance remains unclear.
Methods and Results: We examined 74 consecutive patients who were diagnosed with CS. Basal IVS thickness 
at a point located 10 mm from the aortic annulus was measured. IVS thickness at the left ventricular minor axis level 
(IVS) was also measured according to the recommended procedure of the American Society of Echocardiography. 
Patients were divided into 2 groups based on the presence or absence of basal IVS thinning, which was defined as 
basal IVS ≤4 mm and/or basal IVS/IVS ratio ≤0.6. Basal IVS thinning was observed in 21 patients and was associated 
with greater long-term adverse events during follow-up (5.1±2.5 years), although the baseline characteristics were 
comparable between groups (overall, P<0.01; all-cause death, P=0.53; symptomatic arrhythmias, P<0.01; heart 
failure admission, P=0.027). Multivariate analysis showed basal IVS thinning was an independent determinant of 
long-term adverse events (hazard ratio 2.86, 95% confidence interval 1.31–6.14) even after adjustment for existing 
prognostic variables.
Conclusions: The presence of basal IVS thinning at the time of CS diagnosis was associated with poor long-term 
clinical outcomes, suggesting its prognostic significance in patients with CS.
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patients, the mass of LGE was calculated using the area of 
LGE as previously described.21 The findings of Ga scintigra-
phy, FDG-PET and LGE-CMR were determined by the con-
sensus of 2 experienced radiologists. Venous blood samples 
were serially obtained to measure plasma angiotensin-convert-
ing enzyme (ACE) activity, lysozyme, B-type natriuretic pep-
tide (BNP), hemoglobin, serum creatinine and C-reactive protein 
(CRP) levels.
Echocardiographic Analysis and Definition of Basal IVS 
Thinning
Echocardiography was performed at the time of diagnosis of 
CS. LV end-diastolic and end-systolic dimensions and LV 
ejection fraction (LVEF), as determined by the modified 
Simpson’s method, were evaluated.
Regarding the measurement of IVS thickness, we recorded 
the parasternal long-axis view and measured the IVS thickness 
directly from 2D images based on the recommendation of the 
American Society of Echocardiography (ASE) committee.27
According to the previously proposed definition,24 IVS 
thickness at a point located 10 mm from the aortic annulus 
(basal IVS) was measured. IVS thickness at the LV minor axis 
level (IVS) was also measured, following the recommended 
procedure of the ASE.27 Basal IVS thinning was defined as a 
thickness ≤4 mm and/or a basal IVS/IVS ratio ≤0.6 (Figure 1). 
All echocardiographic findings were interpreted and measured 
by 2 experienced cardiologists.
Study Endpoint and Long-Term Follow-up
The study endpoint was a composite of all-cause death, heart 
failure requiring admission, and symptomatic arrhythmia, which 
was defined as ventricular tachyarrhythmias with clinical 
symptoms and requiring admission, appropriate ICD treatment 
for termination of ventricular fibrillation or sustained ven-
tricular tachycardia, or bradyarrhythmias requiring pacemaker 
implantation. Follow-up data were obtained by dedicated coor-
dinators and investigators from the hospital records, by direct 
contact with patients or patients’ physicians in the hospital or 
outpatient clinic, telephone interview of patients or, if deceased, 
of family members, and by mail.
Statistical Analysis
Continuous data are expressed as mean ± SD. Continuous 
diagnosis of CS.
Even though detection of basal IVS thinning on echocar-
diography is highly specific for CS and has been proposed as 
a potential diagnostic indicator, the determination of basal IVS 
thinning is subjective and a defined cut-off value has not been 
established. Recently, a report comparing mean IVS thickness 
between 175 CS patients and 2,130 control subjects suggested 
that basal IVS thinning defined as a thickness ≤4 mm and/or a 
basal IVS/IVS ratio ≤0.6 could be used as the criterion for 
diagnosing CS with 99.0% specificity and 38.9% sensitivity.24 
However, the long-term prognostic significance of basal IVS 
thinning assessed according to this criterion remains unclear.
The aim of the present study was to clarify the long-term 
prognostic significance of basal IVS thinning in CS patients.
Methods
Study Population
We examined 76 consecutive patients who were admitted 
between May 2003 and December 2012, and diagnosed during 
the hospitalization with CS based on clinical and/or patho-
logical findings, without coronary artery disease, based on the 
diagnostic criteria described in the 2006 revised version of the 
Japanese Ministry of Health and Welfare guidelines for CS.7,25 
Patients in whom basal IVS could not be evaluated by echo-
cardiography because of low-quality images (n=2) were 
excluded. The study protocol conformed with the guidelines 
of the institutional ethics committee (M25-047).
Study Protocol
We collected the following data: age, sex, traditional cardio-
vascular risk factors, cardiovascular medication, history of 
fatal ventricular arrhythmias, advanced AVB, congestive heart 
failure, catheter ablation for ventricular tachyarrhythmias, car-
diac resynchronization therapy (CRT), implantation of perma-
nent pacemaker or implantable cardioverter defibrillator (ICD) 
and extracardiac organ involvement of sarcoidosis, and find-
ings of imaging modalities including Ga scintigraphy, FDG-
PET, and LGE-CMR, at the time of diagnosis. Regarding the 
FDG-PET findings, specific “focal” or “focal on diffuse” 
uptake of FDG was defined as positive, according to the previ-
ous report.26 The presence of LGE on CMR was defined as 
any hyperenhancement in the myocardium. In LGE-positive 
Figure 1.  Representative case of 
evaluation of thinning of the basal 
interventricular septum (IVS) in a 
patient with cardiac sarcoidosis. End-
diastolic thickness of IVS at points A 
and B is first measured, and the A/B 
ratio is then calculated. (A) 10 mm 
distant from the aortic annulus on the 
IVS (basal IVS). (B) LV minor axis 
level on the IVS (IVS). Ao, aorta; LA, 
left atrium; LV, left ventricle; RV, right 
ventricle.
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ing did not significantly differ between the 2 groups (Table 2). 
LGE-CMR was performed in 37 patients (50% of the study 
population). Patients with basal IVS thinning had significantly 
greater %LGE mass in the LV than those without basal IVS 
thinning (Table 2).
Laboratory Data and Medication
Laboratory data, including plasma ACE activity, lysozyme and 
BNP levels, hemoglobin, and serum creatinine and CRP levels 
at the time of diagnosis, were comparable between patients 
with and without basal IVS thinning (Table 3).
Administration of corticosteroids, other immunosuppres-
sants, cardiovascular medication, including β-blockers, ACE 
inhibitors or angiotensin-receptor blockers, diuretics, statins, 
amiodarone and other antiarrhythmic agents, catheter ablation 
for ventricular tachyarrhythmias, CRT, and implantation of a 
permanent pacemaker or ICD were similarly performed in the 
2 groups (Table 3). In patients who received corticosteroid 
therapy, the induction and maintenance doses of corticosteroid 
were comparable between the 2 groups (Table 3).
Long-Term Clinical Outcomes
Patients were followed for 5.1±2.5 years. Kaplan-Meier sur-
vival curves revealed that the presence of basal IVS thinning 
at the time of diagnosis was associated with a higher incidence 
of composite adverse events (all-cause death, symptomatic 
arrhythmias, and heart failure requiring admission) during the 
observation period (Figure 2A). Although basal IVS thinning 
was not a significant determinant of all-cause death (Figure 2B), 
it was an independent determinant of symptomatic arrhyth-
mias and heart failure requiring admission (Figures 2C,D).
Univariate Cox proportional hazards model analysis for 
determinants of composite adverse events revealed that the 
presence of basal IVS thinning, absence of corticosteroid 
therapy, and receiving CRT at the time of diagnosis were the 
variables were compared using unpaired t test or nonparamet-
ric means test. Categorical variables are reported as frequen-
cies with percentages and were compared between groups 
using a chi-squared test. Long-term event-free survival was 
estimated using Kaplan-Meier curves, and a log-rank (Mantel-
Cox) test was used to assess differences according to the pres-
ence or absence of basal IVS thinning at the time of CS 
diagnosis. Cox proportional hazard model analysis, which 
included determinant factors with a P value ≤0.10 in the uni-
variate analysis, was used to assess the association of these 
factors with adverse events. All statistical analyses were per-
formed using SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, 
USA). Statistical significance was defined as P<0.05.
Results
Patients Characteristics
Basal IVS thinning was detected in 21 CS patients (28%). 
Although patients with basal IVS thinning had a higher inci-
dence of fatal ventricular arrhythmias at the time of diagnosis 
than those without, no significant difference between the 2 
groups was detected with respect to sex, incidence of advanced 
AVB, or congestive heart failure at the time of diagnosis. The 
prevalence of traditional cardiovascular risk factors and of 
extracardiac organ involvement of sarcoidosis was similar 
between the 2 groups (Table 1).
Echocardiographic and Other Imaging Findings
Baseline LV end-systolic dimension was larger, and basal IVS 
thickness and basal IVS/IVS ratio were smaller in patients 
with basal IVS thinning than in those without. LV end-dia-
stolic dimension tended to be larger and LVEF was lower in 
patients with basal IVS thinning than in those without. The 
prevalence of AVB of each degree, and the rates of positive 
findings on Ga scintigraphy, PDG-PET and LGE-CMR imag-
Table 1. Baseline Characteristics of Patients With CS
Overall  
(n=74)
IVS thinning  
(n=21)
No IVS thinning  
(n=53) P value
Age, years  62±8.2  63±7.7 62±8.5 0.68
Female, n (%) 48 (65) 13 (62) 35 (66) 0.75
Clinical history
  Hypertension, n (%) 19 (26)   6 (29) 13 (25) 0.73
  Dyslipidemia, n (%) 19 (26)   5 (24) 14 (26) 0.82
  Diabetes mellitus, n (%) 5 (7) 1 (5) 4 (8) 0.62
  Smoking, n (%) 23 (31)   7 (33) 16 (30) 0.80
  Cerebral infarction, n (%) 6 (8)   2 (10) 4 (8) 0.62
  VT/VF, n (%) 22 (30)   4 (19) 18 (34) 0.18
  CHF, n (%) 25 (34) 10 (48) 15 (28) 0.14
NYHA class, degree 0.77
  I–II, n (%) 51 (69) 15 (71) 36 (68)
  III–IV, n (%) 23 (31)   6 (29) 17 (32)
Organ involvement
  Lung, n (%) 29 (39)   7 (33) 22 (42) 0.52
  Skin, n (%) 5 (7) 1 (5) 4 (8) 0.65
  Eye, n (%) 21 (28)   4 (19) 17 (32) 0.24
No. of involved organs 1.8±0.9 1.6±0.8 1.8±0.9 0.23
Cardiac biopsy proven, n (%) 15 (20)   2 (10) 13 (25) 0.15
Continuous variables are presented as mean ± SD. Categorical variables are presented as number of patients (%). 
AV, atrioventricular; CHF, congestive heart failure; CS, cardiac sarcoidosis; IVS, interventricular septum; NYHA, New 
York Heart Association; VF, ventricular fibrillation; VT, ventricular tachycardia.
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Table 2. Baseline Findings of Echocardiography, ECG and Other Imaging Modalities in Patients With CS
Overall  
(n=74)
IVS thinning  
(n=21)
No IVS thinning  
(n=53) P value
Echocardiography
  LVDd, mm 57.2±9.8　　 60.0±10.9 56.2±9.1　　 0.16
  LVDs, mm 45.2±11.9 50.2±12.9 43.2±11.0 0.04
  LVEF, % 34.4±12.9 32.5±12.8 35.1±13.1 0.46
  LAD (mm) 39.6±7.8　　 40.3±8.7　　 41.8±7.0　　 0.55
  Moderate-severe MR, n (%) 15 (20)   4 (19) 11 (21) 0.87
Thickness of IVS at each point
  Basal IVS 7.6±2.6 4.6±1.8 8.7±1.9 <0.01　
  IVS 9.7±2.4 9.3±3.1 9.9±2.2 0.48
  Basal IVS/IVS ratio 0.8±0.3 0.5±0.1 0.9±0.2 <0.01　
ECG
  1st degree AVB, n (%) 10 (14)   3 (14)   7 (13) 0.90
  2nd degree AVB, n (%) 7 (9) 1 (5)   6 (11) 0.38
  3rd degree AVB, n (%) 22 (30)   6 (29) 16 (30) 0.89
Other imaging modalities
  Ga scintigram positive, positive/n (%) 43/69 (62) 12/20 (60) 31/49 (63) 0.80
  FDG-PET positive, positive/n (%) 41/64 (64) 12/18 (67) 29/46 (63) 0.79
  LGE-CMR positive, positive/n (%) 36/37 (97)       9/9 (100) 27/28 (96) 0.57
  %LGE mass (%) 17.0±10.0 26.7±6.7　　 13.6±8.6　　 <0.01　
Continuous variables are presented as mean ± SD. AVB, AV block; FDG-PET, 18F-fluorodeoxy glucose-positron emis-
sion tomography; Ga, gallium; LAD, left atrial diameter; LGE-CMR, late gadolinium enhancement-cardiac magnetic 
resonance; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEF, left ventricular 
ejection fraction; MR, mitral regurgitation. Other abbreviations as in Table 1. Categorical variables are presented as 
number of patients (%).
Table 3. Baseline Laboratory Data and Therapies in Patients With CS
Overall  
(n=74)
IVS thinning  
(n=21)
No IVS thinning 
(n=53) P value
Laboratory data
  Hemoglobin, g/dl 13.0±1.5 12.9±1.4 13.1±1.6 0.75
  Serum creatinine, mg/dl   0.8±0.2   0.8±0.3   0.8±0.2 0.48
  ACE, IU/L 16.2±8.8 15.5±9.9 16.4±8.5 0.76
  Lysozyme, IU/L   8.5±4.4   8.3±4.1   8.6±4.5 0.80
  BNP, pg/ml   242±246   279±272   227±236 0.46
  CRP, mg/dl   0.17±0.22   0.13±0.15   0.19±0.23 0.22
Medications
  Corticosteroids, n (%) 56 (76) 15 (71) 41 (77) 0.61
  Corticosteroid induction dose, mg/day 30.2±2.3 30.7±2.6 30.0±2.2 0.34
  Corticosteroid maintenance dose, mg/day   7.6±4.8   7.8±4.8   7.6±4.8 0.85
  Other immunosuppressants, n (%) 3 (4) 0 (0) 3 (6) 0.08
  ACE inhibitors, n (%) 26 (35) 10 (48) 16 (30) 0.18
  ARBs, n (%) 21 (28)   7 (33) 14 (26) 0.57
  β-blockers, n (%) 47 (64) 11 (52) 36 (68) 0.24
  Diuretics, n (%) 34 (46) 13 (62) 21 (40) 0.09
  Statins, n (%) 21 (28)   5 (24) 16 (30) 0.58
  Amiodarone, n (%) 16 (22)   6 (29) 10 (19) 0.24
  Other antiarrhythmic agents, n (%) 14 (19)   5 (24)   9 (17) 0.53
VT-ablation, n (%)   8 (11)   3 (14) 5 (9) 0.59
CRT, n (%) 13 (18)   5 (24)   8 (15) 0.18
Pacer/ICD, n (%) 43 (58) 11 (52) 32 (60) 0.54
Continuous variables are presented as mean ± SD. Categorical variables are presented as number of patients (%). 
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BNP, B-type natriuretic peptide; CRP, 
C-reactive protein; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator. Other abbre-
viations as in Table 1.
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Figure 2.  Kaplan-Meier analyses of long-term clinical outcomes of patients with cardiac sarcoidosis with or without basal IVS 
thinning. (A) Composite of all-cause death, symptomatic arrhythmias, and heart failure requiring admission; (B) all-cause death; 
(C) symptomatic arrhythmias; (D) heart failure requiring admission. IVS, interventricular septum.
Table 4. Cox Proportional Hazards Model for Determinants of Long-Term Adverse Events in Patients With CS
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Basal IVS thinning 3.12 1.50–6.43 0.01 2.95 1.40–6.19   0.005
Corticosteroid therapy at the time of diagnosis 0.42 0.19–0.99   0.047 0.49 0.21–1.21 0.12
CRT 2.59 1.23–5.40 0.01 1.87 0.83–4.14 0.13
Age ≥64 years 1.38 0.67–2.96 0.38 – – –
Female 1.36 0.64–2.80 0.35 – – –
Organ involvement ≥2 organs 1.66 0.80–3.61 0.17 – – –
LVEF ≤35% 1.10 0.53–2.27 0.79 – – –
Ga scintigram positive 1.18 0.57–2.56 0.94 – – –
FDG-PET positive 0.79 0.38–1.67 0.52 – – –
Hemoglobin ≤13 g/dl 1.47 0.35–4.17 0.55 – – –
Serum creatinine ≥0.7 mg/dl 1.11 0.51–2.66 0.98 – – –
ACE ≥15 IU/L 1.07 0.51–2.20 0.85 – – –
Lysozyme ≥9 μg/L 1.56 0.83–3.00 0.17 – – –
BNP ≥150 pg/ml 1.81 0.88–3.81 0.11 – – –
CI, confidence interval; HR, hazard ratio. Other abbreviations as in Tables 1–3.
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therefore might be an indicator of an advanced state of CS. 
Furthermore, myocardial fibrosis is based on permanent myo-
cardial damage that is usually difficult to ameliorate, even with 
immunosuppressants. Thus, basal IVS thinning may reflect 
advanced and irreversible myocardial damage.
Several analytical modalities other than echocardiography 
have been evaluated for use in risk stratification of CS 
patients.15–21 FDG-PET findings in CS patients are reported to 
be predictive of severe adverse events, including death,16 and 
ventricular arrhythmias.18 LGE-CMR imaging analysis was 
reported as able to detect myocardial scarring, which was 
found to be the best independent predictor of poor outcomes 
in 175 patients with CS.19 Furthermore, the extent of LGE 
evaluated by quantitative CMR analysis was also shown to be 
significantly associated with adverse events, even in CS patients 
who had received steroid treatment.20,21
Relationship Between Basal IVS Thinning and Future 
Arrhythmic Events
In the present study, CS patients with IVS thinning had a 
higher incidence of adverse events, particularly symptomatic 
arrhythmias, over the mean follow-up period of 5.1 years. 
Because the AV node is located near the basal IVS, thinning 
of this area is speculated to be complicated by AVB. How-
ever, the development of ventricular tachyarrhythmias, rather 
than AVB, was more common in CS patients with basal IVS 
thinning compared with those without. Uemura et al also 
reported that basal IVS thinning and the development of AVB 
were not necessarily correlated.33
Significance of Basal IVS Thinning on Echocardiography for 
Clinical Management of CS
Echocardiography is the first-line modality for evaluation of 
patients with CS. Regional wall motion abnormalities, ven-
tricular aneurysms, pericardial effusions, LV dysfunction, and 
basal IVS thinning are commonly observed in CS patients, 
although the sensitivity of these findings varies widely.34–37 
Basal IVS thinning was reported to be indicative of CS; nev-
ertheless, echocardiographic evaluation alone is typically not 
sufficient for a definitive diagnosis of CS. For this reason, a 
multimodality approach should provide higher sensitivity and 
specificity for diagnosing CS.
Despite the observation of basal IVS thinning in patients 
with CS, basal IVS thinning has not been clearly defined. We 
used the criterion previously proposed by Morimoto et al.24 
Basal IVS thinning evaluated by echocardiography using this 
criterion was a strong prognostic determinant of long-term 
only variables with P values ≤0.10. The other examined vari-
ables, including sex, extracardiac involvement, LVEF ≤35% 
(median), positive Ga and/or FDG-PET findings, hemoglobin 
≤13 g/dl (median), serum creatinine ≥0.7 mg/dl (median), ACE 
≥15 IU/L (median), lysozyme ≥9 μg/L (median), and BNP 
≥150 pg/ml (median), were not significant. In the multivariate 
Cox proportional hazards model analysis, the presence of 
basal IVS thinning at the time of CS diagnosis was confirmed 
to be an independent determinant of composite adverse events 
(Table 4).
The type and prevalence of long-term adverse events are 
shown in Table 5. The cause of death in nearly 50% of patients 
with basal IVS thinning was of cardiac origin, despite no sig-
nificant differences between the 2 groups. The majority of 
arrhythmic events were ventricular tachyarrhythmias, which 
were more frequently observed in patients with basal IVS 
thinning than in those without.
Discussion
In the present study population of 74 CS patients, basal IVS 
thinning was present at the time of diagnosis in 28% of 
patients, and was independently associated with a higher inci-
dence of long-term adverse events, especially symptomatic 
ventricular tachyarrhythmias and heart failure requiring admis-
sion. These findings suggest that the criterion for basal IVS 
thinning used in the present study might be useful for identify-
ing high-risk CS patients.
Basal IVS Thinning as Indicator of Long-Term Clinical  
Outcomes
In 1987, Valantine et al first reported that cardiac lesions fre-
quently develop in the basal IVS, which often appeared thin 
and akinetic on cross-sectional echocardiography of CS 
patients.5 It was also reported that the basal IVS was compro-
mised in over 90% of hearts with CS at autopsy.3 Although the 
precise pathophysiology of CS is unclear, it is characterized 
by the formation of inflammatory granulomas in myocardial 
tissue. Macrophages in these localized nodules of inflamma-
tion release several types of cytokines, inducing the recruit-
ment of interferon-gamma-secreting T helper type 1 cells that 
then activate macrophages.28 Severe inflammation in the basal 
IVS region is associated with thickening of the tissue as a 
result of inflammatory edema during the early phase of 
CS;29–31 however, during the late phase, persistent inflamma-
tion may cause progressive loss of myocardial cells and severe 
interstitial fibrosis leading to thinning of the basal IVS,32 which 
Table 5. Long-Term Adverse Events in Patients With CS
Overall  
(n=74)
IVS thinning  
(n=21)
No IVS thinning  
(n=53) P value
Cause of death
  All, n (%)   9 (12)   5 (24) 4 (8) 0.11
  Cardiac, n (%) 5 (7)   2 (10) 3 (6) 0.62
  Noncardiac, n (%) 4 (5)   3 (14) 1 (2) 0.07
Symptomatic arrhythmias
  All, n (%) 17 (23)   9 (43)   8 (15) 0.02
  VT/VF 15 (20)   8 (38)   7 (13) 0.04
  AVB 2 (3) 1 (5)   1 (19) 0.49
Heart failure requiring admission, n (%) 20 (27)   9 (43) 11 (21) 0.05 
Categorical variables are presented as number of patients (%). Abbreviations as in Tables 1,2.
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adverse events in CS patients, indicating that evaluation of 
basal IVS thinning based on this criterion may be useful for 
detecting high-risk CS patients at the time of diagnosis. Such 
patients should be closely monitored and considered for inten-
sive treatment to prevent future adverse cardiac events.
Study Limitations
First, although our CS cohort was relatively large, the sample 
size was still small, thereby limiting the ability to generalize 
the findings and the statistical power for detecting differences 
in negative data. Second, because patients without a pace-
maker, ICD, or CRT were not always monitored by 24-h 
electrocardiography, it is possible that the incidence of several 
tachy- and bradyarrhythmias might have been underestimated. 
For this reason, the study endpoints regarding arrhythmic 
events were defined as either symptomatic ventricular arrhyth-
mias requiring admission, ICD treatment for termination of 
ventricular fibrillation or sustained ventricular tachycardia or 
bradyarrhythmias requiring permanent pacemaker implanta-
tion. Third, LGE-CMR was performed for only half of the CS 
patients; therefore, the comparison between the 2 groups in 
terms of the extent of LGE would be underpowered. Fourth, 
although LVEF is one of the most important prognostic indi-
cators in various heart diseases, it was not associated with 
clinical outcome in this study. The reason could be explained 
by the fact that the average LVEF in our population was 34.4%, 
which was lower than in a recent large-scale nationwide CS 
study (44.9%) showing the prognostic effect of decreased 
LVEF (<35%) at diagnosis on long-term clinical outcome.38 
This might be one of the reasons for the nonsignificant effect 
of LVEF on clinical outcomes in the current study. Finally, 
because of the retrospective nature of this study, there was a 
potential for sampling bias and incomplete data, and further 
prospective studies in larger populations are warranted.
Conclusions
The presence of basal IVS thinning at the time of CS diagnosis 
was associated with poor long-term clinical outcomes, par-
ticularly with respect to future ventricular tachyarrhythmias 
and heart failure requiring admission, suggesting that this 
characteristic has considerable prognostic significance in patients 
with CS.
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